Why Exact Sciences Shares Rallied 10.2% in August
After the company reported better-than-expected top- and bottom-line second-quarter results in late July and updated investors on its strategy at Cannacord's 37th annual growth conference on Aug. 9, shares of Exact Sciences (NASDAQ: EXAS) jumped 10.2% last month, according to S&P Global Market Intelligence.
Guidelines call for everyone between ages 50 to 74 to be on a colon cancer screening "schedule," yet millions of Americans are failing to follow through on being tested, and as a result, more cases of late-stage colon cancer are being diagnosed than there should be.
IMAGE SOURCE: GETTY IMAGES.
Source: Fool.com
Exact Sciences Aktie
60,88 €
-0,02 %
Mehrere Buy-Einschätzungen geben Exact Sciences den Vorteil, ohne Sell-Einschätzungen.
Das Community-Kursziel von 76 € für Exact Sciences deutet auf eine deutliche Steigerung um mehr als 20% gegenüber dem aktuellen Kurs von 60.88 € hin.
